Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Brain : a Journal of Neurology
|
August 22, 2006
Remyelination is extensive in a subset of multiple sclerosis patients
Peter Patrikios, Christine Stadelmann, Alexandra Kutzelnigg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 6, 2014
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
Lukas Haider, Constantina Simeonidou, Günther Steinberger, et al.
Journal of Neuropathology and Experimental Neurology
|
September 8, 2006
Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis
Sonja Hochmeister, Roland Grundtner, Jan Bauer, et al.
International Journal of Bipolar Disorders
|
November 1, 2014
Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study
Alexandra Kutzelnigg, Martin Kopeinig, Chih-Ken Chen, et al.
Brain Pathology (Zurich, Switzerland)
|
May 12, 2007
Widespread demyelination in the cerebellar cortex in multiple sclerosis
Alexandra Kutzelnigg, Jens C Faber-Rod, Jan Bauer, et al.
Human Brain Mapping
|
October 26, 2016
Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET
Thomas Vanicek, Alexandra Kutzelnigg, Cecile Philippe, et al.
JAMA Psychiatry
|
October 23, 2014
The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography
Thomas Vanicek, Marie Spies, Christina Rami-Mark, et al.
The Lancet. Neurology
|
June 21, 2020
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
European Journal of Clinical Pharmacology
|
May 10, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Markus Zeitlinger, Martin Bauer, Roman Reindl-Schwaighofer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 4, 2020
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
Wassilios G Meissner, Anne Pavy-Le Traon, Alexandra Foubert-Samier, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Brain : a Journal of Neurology
|
August 22, 2006
Remyelination is extensive in a subset of multiple sclerosis patients
Peter Patrikios, Christine Stadelmann, Alexandra Kutzelnigg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 6, 2014
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
Lukas Haider, Constantina Simeonidou, Günther Steinberger, et al.
Journal of Neuropathology and Experimental Neurology
|
September 8, 2006
Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis
Sonja Hochmeister, Roland Grundtner, Jan Bauer, et al.
International Journal of Bipolar Disorders
|
November 1, 2014
Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study
Alexandra Kutzelnigg, Martin Kopeinig, Chih-Ken Chen, et al.
Brain Pathology (Zurich, Switzerland)
|
May 12, 2007
Widespread demyelination in the cerebellar cortex in multiple sclerosis
Alexandra Kutzelnigg, Jens C Faber-Rod, Jan Bauer, et al.
Human Brain Mapping
|
October 26, 2016
Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET
Thomas Vanicek, Alexandra Kutzelnigg, Cecile Philippe, et al.
JAMA Psychiatry
|
October 23, 2014
The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography
Thomas Vanicek, Marie Spies, Christina Rami-Mark, et al.
The Lancet. Neurology
|
June 21, 2020
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
European Journal of Clinical Pharmacology
|
May 10, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Markus Zeitlinger, Martin Bauer, Roman Reindl-Schwaighofer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 4, 2020
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
Wassilios G Meissner, Anne Pavy-Le Traon, Alexandra Foubert-Samier, et al.
Page
of 3